Hepatorenal Syndrome (HRS)

Quick Answer

Hepatorenal Syndrome (HRS) is a form of functional renal failure occurring in patients with advanced liver disease and portal hypertension, characterised by intense renal vasoconstriction in the absence of intrinsic renal pathology. It represents the severe end of the circulatory dysfunction spectrum in decompensated cirrhosis.

Key Clinical Features:

• AKI in setting of decompensated cirrhosis with ascites
• No response to volume expansion with albumin (1 g/kg for 2 days)
• Absence of shock, nephrotoxic drugs, or structural renal disease
• Low urine sodium (<10 mmol/L), bland urinary sediment

Emergency Management:

1. Volume expansion with 20-25% albumin (1 g/kg/day for 2 days, max 100g/day)
2. Vasoconstrictors: Terlipressin (1-2 mg IV q4-6h) OR Noradrenaline infusion
3. Identify and treat precipitants (SBP, GI bleed, large volume paracentesis)
4. Urgent hepatology/transplant referral
5. Consider RRT as bridge to transplant (not for long-term dialysis)

Mortality:

• Untreated: 80% at 2 weeks (HRS-AKI), 50% at 6 months (HRS-CKD)
• With vasoconstrictors: 50% response, 40-50% 90-day mortality
• Post-liver transplant: 65-75% 1-year survival

Must-Know Facts:

• HRS is a diagnosis of exclusion - rule out ATN, prerenal, obstruction, nephrotoxins first
• Splanchnic vasodilation leads to systemic hypotension and compensatory renal vasoconstriction
• Terlipressin improves renal function in 40-50% but does NOT reduce mortality without transplant
• Liver transplantation is the only definitive treatment
• MELD score >30 predicts poor response to medical therapy

---

CICM Exam Focus

What Examiners Expect

Second Part Written (SAQ):

Common SAQ stems:

• "A 55-year-old male with alcoholic cirrhosis and ascites presents to ICU with AKI. Serum creatinine 285 umol/L (baseline 95), urine output 250 mL/24h, Na 128 mmol/L. Discuss your diagnostic approach and management."
• "Outline the pathophysiology of hepatorenal syndrome and the rationale for pharmacological management."
• "Compare and contrast HRS-AKI (Type 1) and HRS-CKD (Type 2). Discuss the ICA-AKI consensus criteria."
• "Discuss the role of TIPS, vasoconstrictors, and liver transplantation in HRS management."

Expected depth:

• Systematic approach to AKI in cirrhosis (ICA-AKI staging)
• Pathophysiology: splanchnic vasodilation, RAAS activation, renal vasoconstriction cascade
• Evidence for terlipressin (CONFIRM, REVERSE trials) with Australian/NZ context (noradrenaline as alternative)
• Liver transplant assessment and contraindications
• Prognostic scoring (MELD, Child-Pugh)

Second Part Hot Case:

Typical presentations:

• Day 3 ICU patient with decompensated cirrhosis, ascites, rising creatinine despite albumin
• Post-SBP patient with oliguria and hypotension on noradrenaline
• Jaundiced patient with variceal bleed and worsening renal function

Examiners assess:

• Recognition of precipitants (SBP, GI bleed, LVP without albumin replacement)
• Volume status assessment in cirrhotic patient (challenging - peripheral oedema despite intravascular depletion)
• Understanding of circulatory dysfunction model
• Appropriate escalation: vasoconstrictor therapy, RRT criteria, transplant referral
• Family communication regarding prognosis

Second Part Viva:

Expected discussion areas:

• Pathophysiology: arterial underfilling hypothesis, splanchnic vasodilation, RAAS/SNS activation
• Differential diagnosis: distinguishing HRS from ATN (FENa, urinalysis, response to albumin)
• Pharmacology: terlipressin vs noradrenaline - mechanism, dosing, adverse effects
• Role of TIPS: evidence, indications, contraindications
• RRT in HRS: bridge to transplant, futility considerations
• Transplant assessment: MELD score, contraindications, combined liver-kidney transplant criteria
• Indigenous health: higher cirrhosis rates, access to transplant services

Examiner expectations:

• Safe, consultant-level decision-making
• Evidence-based practice with guideline/trial citations
• Understanding that HRS is a systemic circulatory disorder, not a primary renal disease
• Appreciation of futility without transplant candidacy
• Cultural sensitivity in discussing prognosis

Common Mistakes

• Diagnosing HRS without ruling out other causes of AKI (especially ATN from hypotension/sepsis)
• Using FENa in patients on diuretics (unreliable - use FEUrea or clinical response to albumin)
• Delaying vasoconstrictor therapy while "optimising volume status"
• Continuing medical therapy when patient is not a transplant candidate (futility)
• Initiating long-term RRT without transplant plan
• Forgetting SBP as precipitant (always do diagnostic paracentesis)
• Confusing old (Type 1/2) and new (HRS-AKI/HRS-CKD) nomenclature

---

Key Points

Must-Know Facts

1. Definition: HRS is functional renal failure in advanced liver disease caused by renal vasoconstriction secondary to systemic and splanchnic arterial vasodilation - kidneys are structurally normal.

2. ICA-AKI 2015 Classification: HRS-AKI (formerly Type 1) = rapidly progressive, doubling of creatinine within 2 weeks; HRS-CKD (formerly Type 2) = slowly progressive, stable low-grade renal dysfunction.

3. Diagnostic Criteria (ICA 2015): Cirrhosis with ascites + AKI per KDIGO criteria + no response to 2 days albumin (1 g/kg) + absence of shock/nephrotoxins + no structural renal disease.

4. Pathophysiology Core: Splanchnic vasodilation (NO, bacterial translocation) -> arterial underfilling -> compensatory RAAS/SNS/ADH activation -> intense renal vasoconstriction.

5. Common Precipitants: Spontaneous bacterial peritonitis (SBP - 30-40%), GI bleeding, large volume paracentesis without albumin replacement, excessive diuretic use, NSAIDs.

6. Treatment Triad: (1) Albumin (volume expansion), (2) Vasoconstrictors (terlipressin or noradrenaline), (3) Liver transplantation (definitive).

7. Vasoconstrictor Evidence: CONFIRM trial showed terlipressin improved HRS reversal (32% vs 17%) but increased respiratory failure; REVERSE showed similar efficacy to noradrenaline.

8. Australian Context: Noradrenaline is first-line in many Australian ICUs due to cost, availability, and familiarity; terlipressin not PBS-listed for HRS.

9. RRT Role: Bridge to transplant only - does NOT improve outcomes without transplant; consider futility if not a transplant candidate.

10. Prognosis: MELD score >30, bilirubin >171 umol/L, non-response to vasoconstrictors at 72h predict poor outcomes; median survival without transplant 1-2 months.

Memory Aids

Mnemonic "HEPATO" for HRS Diagnostic Criteria:

• H: Hepatic cirrhosis with ascites present
• E: Exclusion of other causes (ATN, obstruction, nephrotoxins)
• P: Poor response to albumin expansion (48h trial)
• A: Absence of shock state
• T: Tubular function preserved (low urine sodium <10 mmol/L)
• O: Oliguria/AKI criteria met

"STARS" for HRS Precipitants:

• S: SBP (spontaneous bacterial peritonitis) - most common
• T: Transjugular procedures/taps (large volume paracentesis)
• A: Alcohol binge/acute alcoholic hepatitis
• R: Renal insults (NSAIDs, aminoglycosides, contrast)
• S: Splanchnic bleeding (variceal haemorrhage)

---

Definition & Epidemiology

Definition

Hepatorenal Syndrome (HRS) is defined as the development of renal impairment in patients with advanced liver disease (cirrhosis) and portal hypertension, in the absence of identifiable cause of renal failure. It represents a form of functional renal failure characterised by intense intrarenal vasoconstriction and systemic circulatory dysfunction.

ICA-AKI 2015 Diagnostic Criteria (International Club of Ascites) (PMID: 26235643):

1. Presence of cirrhosis with ascites
2. Diagnosis of AKI according to ICA-AKI criteria:
   • Stage 1: Increase in sCr ≥26.5 umol/L (0.3 mg/dL) OR increase ≥1.5-2x from baseline
   • Stage 2: Increase in sCr >2-3x from baseline
   • Stage 3: Increase in sCr >3x from baseline OR sCr ≥353.6 umol/L (4.0 mg/dL) with acute increase ≥26.5 umol/L OR initiation of RRT
3. No response after 2 consecutive days of diuretic withdrawal and plasma volume expansion with albumin (1 g/kg body weight, maximum 100 g/day)
4. Absence of shock
5. No current or recent use of nephrotoxic drugs (NSAIDs, aminoglycosides, iodinated contrast)
6. No macroscopic signs of structural kidney injury:
   • No proteinuria (>500 mg/day)
   • No microhaematuria (>50 RBCs per high power field)
   • Normal renal ultrasound

Classification (2015 ICA Consensus):

Epidemiology

International Data (PMID: 29753639, 33657293):

• Incidence: 18-40% of patients with cirrhosis and ascites develop HRS within 5 years
• Annual incidence in decompensated cirrhosis: 8-10%
• HRS-AKI occurs in 25-50% of cirrhotic patients with AKI
• Prevalence in ICU patients with decompensated cirrhosis: 35-40%

Australian/NZ Data (ANZICS APD, Australian Liver Foundation):

• Cirrhosis-related ICU admissions: Increasing trend, estimated 2,500-3,000 admissions/year
• HRS diagnosed in approximately 15-20% of cirrhotic ICU admissions
• Liver transplant waitlist: ~450 patients nationally at any time
• Median wait time for liver transplant: 4-6 months
• HRS is indication for ~15% of combined liver-kidney transplants

Indigenous Health Considerations (PMID: 24995628):

• Aboriginal and Torres Strait Islander peoples: 2-3x higher rates of chronic liver disease and cirrhosis
• Higher prevalence of hepatitis B (especially in Northern Territory)
• Higher rates of alcohol-related liver disease
• Younger age at presentation with decompensated cirrhosis
• Significant barriers to accessing transplant services (geographic, cultural, socioeconomic)
• Lower rates of transplant referral and listing
• Māori populations (NZ): 2x higher liver disease mortality, similar access barriers

Risk Factors for HRS Development:

Non-modifiable:

• Severity of liver disease (Child-Pugh C, MELD >20)
• Prior episode of HRS
• Hyponatraemia (<130 mmol/L)
• Low mean arterial pressure (<80 mmHg)

Modifiable/Precipitant:

• Spontaneous bacterial peritonitis (most common precipitant - 30-40%)
• Large volume paracentesis without albumin replacement
• Gastrointestinal bleeding
• NSAIDs, aminoglycosides, iodinated contrast
• Excessive diuretic use
• Acute alcoholic hepatitis

Outcomes:

• HRS-AKI (Type 1) untreated: Median survival 2 weeks, 80% mortality at 3 months
• HRS-AKI with vasoconstrictors: 40-50% response rate, 50% 90-day mortality
• HRS-CKD (Type 2) untreated: Median survival 6 months
• Post-liver transplant: 65-75% 1-year survival, 50-60% 5-year survival
• Combined liver-kidney transplant: Similar outcomes to liver-alone when renal dysfunction <12 weeks

---

Applied Basic Sciences

This section bridges First Part basic sciences with Second Part clinical practice

Anatomy

Relevant Hepatic Anatomy:

Portal Venous System:

• Portal vein formed by confluence of superior mesenteric vein and splenic vein behind pancreatic neck
• Normal portal pressure: 5-10 mmHg; portal hypertension defined as >10 mmHg
• Hepatic venous pressure gradient (HVPG): Portal pressure minus hepatic venous wedge pressure
• HVPG >10 mmHg = clinically significant portal hypertension
• HVPG >12 mmHg = risk of variceal bleeding and ascites formation

Splanchnic Circulation:

• Receives 25% of cardiac output at rest
• Three main arteries: coeliac trunk, superior mesenteric artery, inferior mesenteric artery
• Extensive collateral network allows development of varices in portal hypertension
• Splanchnic vasodilation is central to HRS pathophysiology

Renal Vascular Anatomy:

• Renal blood flow: 20-25% of cardiac output (~1200 mL/min)
• Afferent arteriole: Regulates glomerular perfusion pressure
• Efferent arteriole: Regulated by angiotensin II to maintain GFR
• Juxtaglomerular apparatus: Renin release in response to decreased perfusion pressure

Physiology

Normal Renal Blood Flow Regulation:

The kidney maintains stable GFR across MAP 80-180 mmHg through autoregulation:

1. Myogenic response: Afferent arteriole constricts in response to increased pressure
2. Tubuloglomerular feedback: Macula densa senses NaCl delivery, modulates afferent tone
3. Hormonal regulation: Angiotensin II (efferent constriction), prostaglandins (afferent dilation)

Normal autoregulation fails when:

• MAP <80 mmHg (autoregulatory threshold exceeded)
• Severe RAAS activation (overwhelms prostaglandin-mediated vasodilation)
• Prostaglandin synthesis inhibited (NSAIDs)

Pathophysiology

The Arterial Underfilling Hypothesis (PMID: 24583062):

HRS pathophysiology centres on the concept of "arterial underfilling"

• effective arterial blood volume is reduced despite total body fluid overload.

Step 1: Portal Hypertension and Splanchnic Vasodilation

Portal hypertension leads to:

• Increased shear stress on mesenteric vessels
• Upregulation of endothelial nitric oxide synthase (eNOS)
• Increased nitric oxide (NO) production
• Splanchnic arterial vasodilation

Additional vasodilators:

• Carbon monoxide (from haem oxygenase)
• Endogenous cannabinoids
• Prostaglandins (PGI2, PGE2)
• Glucagon
• Bacterial translocation products (endotoxin stimulates further NO release)

Step 2: Systemic Circulatory Dysfunction

As cirrhosis progresses:

• Splanchnic blood pooling increases
• Effective arterial blood volume decreases
• Central blood volume and cardiac preload decrease
• Cardiac output initially increases (hyperdynamic circulation) but becomes insufficient
• Systemic vascular resistance decreases

The Hyperdynamic Circulation of Cirrhosis:

• High cardiac output (6-8 L/min initially)
• Low systemic vascular resistance
• Low mean arterial pressure
• Wide pulse pressure
• Warm peripheries
• BUT: Inadequate effective circulating volume

Step 3: Compensatory Neurohormonal Activation

Arterial baroreceptors sense "underfilling" and trigger:

Renin-Angiotensin-Aldosterone System (RAAS):

• Intense activation in advanced cirrhosis
• Angiotensin II: Systemic vasoconstriction, renal efferent >afferent effect
• Aldosterone: Sodium and water retention
• Effect on kidney: Efferent arteriole constriction maintains GFR initially

Sympathetic Nervous System (SNS):

• Increased renal sympathetic nerve activity
• Direct renal vasoconstriction (alpha-1 receptors)
• Renin release stimulation
• Sodium reabsorption enhancement

Arginine Vasopressin (AVP/ADH):

• Non-osmotic release due to arterial underfilling
• V1a receptors: Vasoconstriction
• V2 receptors: Free water retention (contributes to hyponatraemia)

Step 4: Renal Vasoconstriction and HRS

When compensatory mechanisms are overwhelmed:

• Intense renal afferent arteriole vasoconstriction
• Decreased renal blood flow (despite normal/high cardiac output)
• Decreased glomerular filtration rate
• Sodium and water retention exacerbate ascites

Critical Balance:

• Renal prostaglandins (PGE2, PGI2) normally counteract vasoconstriction
• In HRS, vasoconstrictors overwhelm vasodilatory prostaglandins
• NSAIDs precipitate HRS by blocking protective prostaglandin synthesis
• This explains why HRS kidneys function normally when transplanted into non-cirrhotic recipients

Bacterial Translocation and Inflammation (PMID: 26235643):

In advanced cirrhosis:

• Gut barrier dysfunction from portal hypertension
• Bacterial translocation from gut to mesenteric lymph nodes
• Endotoxin (lipopolysaccharide, LPS) enters systemic circulation
• LPS activates toll-like receptors
• Further NO production exacerbates vasodilation
• Systemic inflammatory response syndrome (SIRS)

This explains why SBP is the most common precipitant of HRS - infection causes acute worsening of the already precarious circulatory state.

Why Kidneys Are Structurally Normal:

In HRS:

• No acute tubular necrosis (unless prolonged/severe)
• No glomerular pathology
• No interstitial nephritis
• Kidneys demonstrate intense cortical vasoconstriction on imaging
• When HRS kidneys are transplanted into non-cirrhotic recipients, they function normally
• This confirms HRS is a functional, not structural, renal disorder

Pharmacology

Key ICU Drugs for HRS:

1. Terlipressin

• Class: Vasopressin analogue (V1a receptor agonist with some V2 activity)
• Mechanism:
  • V1a receptors on splanchnic vessels cause vasoconstriction
  • Reduces splanchnic blood pooling
  • Redistributes blood to effective arterial circulation
  • Reduces RAAS and SNS activation
  • Decreases renal vasoconstriction
• ICU Indication: First-line vasoconstrictor for HRS (European guidelines)
• Dosing:
  • "Initial: 1 mg IV q4-6h OR 2 mg IV q12h"
  • Titrate up to 2 mg q4-6h if no response at 48-72h
  • "Continuous infusion: 2-4 mg/24h (some protocols)"
  • "Maximum: 12 mg/day"
• Monitoring:
  • ECG (ischaemia, arrhythmias)
  • SpO2 (respiratory complications)
  • Serum sodium
  • Liver function
  • Signs of digital/mesenteric ischaemia
• Adverse Effects:
  • "Cardiovascular: Ischaemia (20-25%), arrhythmias, hypertension"
  • "Respiratory: ARDS, respiratory failure (15% in CONFIRM trial)"
  • "GI: Abdominal pain, diarrhoea, mesenteric ischaemia"
  • "Peripheral: Digital ischaemia, skin necrosis"
  • Hyponatraemia
• Contraindications:
  • Ischaemic heart disease
  • Peripheral vascular disease
  • Cerebrovascular disease
  • Uncontrolled hypertension
• PBS/TGA: TGA approved but NOT PBS listed for HRS (cost ~$150/vial)
• Key Evidence:
  • "CONFIRM trial (PMID: 33657293): Terlipressin + albumin vs placebo + albumin; improved HRS reversal (32% vs 17%, p<0.001) but increased respiratory failure (11% vs 3%); no mortality difference"
  • "REVERSE trial (PMID: 29753639): Terlipressin vs noradrenaline; similar efficacy (40% vs 43% response)"

2. Noradrenaline

• Class: Catecholamine (alpha-1 predominant)
• Mechanism:
  • "Alpha-1: Splanchnic and systemic vasoconstriction"
  • Less specific for splanchnic bed than terlipressin
  • Redistributes blood from splanchnic to central circulation
  • Reduces renal vasoconstriction via reduced RAAS activation
• ICU Indication: First-line in Australian/NZ ICUs due to familiarity, availability, cost
• Dosing:
  • "Start: 0.5-1 mcg/min (0.01-0.02 mcg/kg/min)"
  • "Titrate: To MAP increase of 10 mmHg or MAP >65 mmHg"
  • "Target: MAP 75-85 mmHg"
  • "Maximum: 3 mcg/kg/min"
  • "Duration: Minimum 7-14 days in responders"
• Monitoring:
  • Arterial line mandatory
  • ECG continuous
  • Urine output hourly
  • Lactate serial
  • Extremity perfusion
• Adverse Effects:
  • Arrhythmias
  • Myocardial ischaemia
  • Peripheral ischaemia
  • Hypertension
  • Splanchnic ischaemia
• PBS/TGA: Standard ICU drug, widely available

3. Albumin (Human Albumin Solution 20-25%)

• Class: Plasma volume expander, colloid
• Mechanism:
  • Expands plasma volume (more effective than crystalloid in cirrhosis)
  • Increases effective arterial blood volume
  • Binds and removes inflammatory mediators
  • Reduces bacterial translocation
  • Antioxidant and immunomodulatory effects
• ICU Indication: Essential component of HRS treatment (with vasoconstrictors)
• Dosing:
  • "Diagnostic/initial: 1 g/kg/day for 2 days (maximum 100 g/day)"
  • "With vasoconstrictors: 20-40 g/day"
  • "Post-LVP: 6-8 g per litre removed (>5L removed)"
  • "SBP prophylaxis: 1.5 g/kg at diagnosis, 1 g/kg on day 3"
• Monitoring:
  • Signs of volume overload (pulmonary oedema, worsening ascites)
  • Serum albumin (target >30 g/L uncertain)
• Adverse Effects:
  • Pulmonary oedema
  • Allergic reactions (rare)
  • Transmission of infectious agents (theoretical)
• Key Evidence:
  • "ATTIRE trial (PMID: 33631097): Targeted albumin (>30 g/L) vs standard care in decompensated cirrhosis - NO difference in infection, renal dysfunction, or mortality; increased adverse events with aggressive albumin"
  • "ANSWER trial (PMID: 35396197): Long-term weekly albumin reduced mortality and complications in outpatients with ascites"

4. Midodrine

• Class: Alpha-1 adrenergic agonist (oral)
• Mechanism: Peripheral vasoconstriction, increases SVR and MAP
• ICU Indication: Second-line, usually outpatient/ward-based adjunct
• Dosing: 7.5-15 mg PO TDS
• Adverse Effects: Supine hypertension, urinary retention, bradycardia
• Role: Limited in ICU; may be used for weaning off IV vasoconstrictors or in HRS-CKD

5. Octreotide

• Class: Somatostatin analogue
• Mechanism: Reduces splanchnic blood flow, decreases glucagon
• ICU Indication: Often combined with midodrine in US practice; less commonly used in Australia
• Dosing: 100-200 mcg SC TDS or 25-50 mcg/h IV
• Evidence: Weaker than terlipressin; used when terlipressin unavailable

Pathology

Histopathology (PMID: 22152276):

Liver:

• Cirrhosis: Fibrous septa, regenerative nodules, architectural distortion
• Varies by aetiology (micronodular in alcohol, macronodular in viral)
• Active inflammation in acute-on-chronic liver failure

Kidney in HRS:

• Glomeruli: Normal appearance or mild ischaemic changes
• Tubules: Mild ischaemic injury, occasional ATN if prolonged
• Vessels: Intense afferent arteriolar constriction (functional, not structural)
• Interstitium: Generally normal
• Key Point: Renal histology is near-normal despite severe dysfunction

When Kidneys Are Transplanted:

• HRS kidneys transplanted from cirrhotic donors into non-cirrhotic recipients function normally
• Confirms that HRS is a haemodynamic/functional disorder
• Supports aggressive treatment as bridge to transplant

Bile Cast Nephropathy:

• Separate entity from HRS
• Bile casts obstruct tubules in severe hyperbilirubinaemia
• Direct tubular toxicity from bile acids
• May coexist with HRS

---

Clinical Presentation

ICU Admission Scenarios

Typical Presentations:

Scenario 1: SBP-Precipitated HRS

• History: Known cirrhosis with ascites, presents with abdominal pain, fever, altered mental status
• Examination: Febrile, jaundiced, distended abdomen with tenderness, peripheral oedema, asterixis
• Investigations: Raised creatinine (doubled from baseline), ascitic fluid WCC >250/mm3 (PMN predominant), positive culture
• Severity: High - requires urgent antibiotics, albumin, consideration of vasoconstrictors

Scenario 2: Post-Variceal Bleed

• History: Haematemesis in known portal hypertension, resuscitated in ED, now oliguric
• Examination: Pallor, tachycardia, hypotension, splenomegaly, caput medusae, ascites
• Investigations: Rising creatinine, anaemia, coagulopathy, low urine output despite resuscitation
• Severity: Moderate-High - bleeding controlled, now developing renal dysfunction

Scenario 3: Decompensated Cirrhosis with Progressive Renal Failure

• History: Increasing abdominal distension, reduced urine output over weeks, confusion
• Examination: Jaundiced, ascites (tense), peripheral oedema, hepatic encephalopathy grade 2-3
• Investigations: Creatinine rising over 7 days, hyponatraemia, albumin trial with no response
• Severity: High - meets HRS criteria, needs vasoconstrictor therapy and transplant evaluation

Symptoms & Signs

History:

• Chief complaint: Reduced urine output, increasing abdominal distension, confusion
• Associated symptoms:
  • Nausea, anorexia (uraemia, liver failure)
  • Abdominal pain (SBP, tense ascites)
  • Lower limb swelling
  • Easy bruising/bleeding (coagulopathy)
  • Sleep-wake reversal, confusion (hepatic encephalopathy)
• Time course: Usually subacute (days to weeks); acute if precipitated by infection/bleed
• Past medical history:
  • Cirrhosis aetiology (alcohol, viral hepatitis B/C, NAFLD, autoimmune)
  • Prior decompensation (ascites, variceal bleeding, encephalopathy)
  • Previous HRS episodes
  • Cardiac disease (contraindication to terlipressin)

Examination:

General:

• Appearance: Cachectic, jaundiced, asterixis
• Vital signs: Hypotension (MAP often <75 mmHg), tachycardia, warm peripheries (hyperdynamic circulation)

A - Airway:

• Usually patent unless severe encephalopathy
• May require intubation for Grade 4 encephalopathy

B - Breathing:

• Respiratory rate: May be elevated (metabolic acidosis compensation)
• Hepatic hydrothorax: Decreased breath sounds at right base (80% right-sided)
• Work of breathing: Increased if pulmonary oedema from overzealous fluid resuscitation

C - Circulation:

• Heart rate: Tachycardia (compensatory)
• Blood pressure: Low MAP despite high cardiac output
• Perfusion: Warm peripheries, wide pulse pressure, bounding pulses
• JVP: Often low despite total body fluid overload (intravascular depletion)
• Heart sounds: May have systolic murmur (hyperdynamic flow)

D - Disability/Neurology:

• GCS/hepatic encephalopathy grade:
  • "Grade 1: Altered sleep, mild confusion"
  • "Grade 2: Lethargy, personality change, asterixis"
  • "Grade 3: Somnolence, disorientation, gross asterixis"
  • "Grade 4: Coma"
• Asterixis: "Liver flap"
• negative myoclonus on wrist extension
• Fetor hepaticus: Sweet, musty breath odour

E - Exposure/Everything Else:

• Temperature: May be hypothermic (impaired thermoregulation) or febrile (infection)
• Skin:
  • Jaundice (bilirubin >50 umol/L visible)
  • Spider naevi (>5 significant)
  • Palmar erythema
  • Bruising (coagulopathy)
  • Caput medusae (periumbilical collaterals)
• Abdomen:
  • Ascites (shifting dullness, fluid thrill)
  • Hepatomegaly (may be small/cirrhotic) or splenomegaly
  • Abdominal tenderness (SBP)
• Extremities: Peripheral oedema, muscle wasting
• Genitalia: Scrotal oedema

Severity Scoring

MELD Score (Model for End-Stage Liver Disease) (PMID: 12512033):

MELD = 3.78 × ln[bilirubin (mg/dL)] + 11.2 × ln[INR] + 9.57 × ln[creatinine (mg/dL)] + 6.43

Interpretation:

• MELD <15: Low 3-month mortality (<5%)
• MELD 15-25: Moderate mortality (6-20%)
• MELD 25-40: High mortality (20-60%)
• MELD >40: Very high mortality (>70%)

Child-Pugh Score:

• Child-Pugh A (5-6): Well-compensated, 1-year survival 100%
• Child-Pugh B (7-9): Significant compromise, 1-year survival 80%
• Child-Pugh C (10-15): Decompensated, 1-year survival 45%

CLIF-C ACLF Score (for acute-on-chronic liver failure) (PMID: 25038122):

Incorporates organ failures (liver, kidney, brain, coagulation, circulation, respiratory) with age and WBC count. Better predicts short-term mortality in ACLF.

Differential Diagnosis

Key Differentials:

1. Prerenal AKI (Hypovolaemia):

   • Distinguished from HRS by: Response to volume expansion with albumin (creatinine improves)
   • Key features: History of fluid losses, more severe hypotension, responds to crystalloid/albumin
   • Investigations: FENa <1%, urine osmolality >500, improves with volume

2. Acute Tubular Necrosis (ATN):

   • Distinguished from HRS by: Muddy brown casts on urinalysis, FENa >2%, urine Na >40 mmol/L
   • Key features: History of prolonged hypotension, septic shock, nephrotoxin exposure
   • Course: Recovery expected in 2-4 weeks with supportive care
   • Challenge: ATN can coexist with or develop from prolonged HRS

3. Drug-Induced Nephrotoxicity:

   • Agents: NSAIDs (precipitate HRS by blocking prostaglandins), aminoglycosides, amphotericin B, iodinated contrast
   • Distinguished by: Temporal relationship to drug exposure, improvement with cessation
   • NSAIDs may precipitate true HRS rather than direct nephrotoxicity

4. Obstructive Uropathy:

   • Distinguished by: Hydronephrosis on ultrasound, history of urological symptoms
   • Consider: Retroperitoneal fibrosis from pancreatitis (common in alcoholic cirrhosis)

5. Glomerulonephritis:

   • Key features: Active urinary sediment (RBC casts, proteinuria), associated systemic features
   • Consider: IgA nephropathy (associated with alcoholic cirrhosis), cryoglobulinaemia (HCV-related)

6. Acute Interstitial Nephritis:

   • Key features: Recent medication exposure (antibiotics, PPIs), eosinophilia, eosinophiluria, WBC casts
   • Distinguished by: May have rash, fever, eosinophils

7. Cholemic Nephropathy (Bile Cast Nephropathy):

   • Key features: Severe hyperbilirubinaemia (>340 umol/L), bile-stained casts
   • Distinguished by: Direct bilirubin toxicity to tubules, different from HRS mechanism

Diagnostic Algorithm to Distinguish HRS from ATN:

---

Investigations

Laboratory Investigations

Bedside Tests:

Arterial Blood Gas:

• pH: Often low (metabolic acidosis from lactate or uraemia)
• PaCO2: Low (respiratory compensation)
• PaO2: May be low (hepatopulmonary syndrome, hepatic hydrothorax)
• HCO3: Low (metabolic acidosis)
• Lactate: Often elevated (impaired hepatic clearance, tissue hypoperfusion)
• Base excess: Negative

Typical ABG: pH 7.32, PaCO2 28, PaO2 75 (FiO2 0.4), HCO3 16, BE -10, Lactate 3.5

Blood Tests:

Renal Function:

• Urea: Elevated (typically urea:creatinine ratio high in HRS due to increased hepatic urea production and prerenal component)
• Creatinine: Elevated (but may underestimate renal dysfunction due to low muscle mass and reduced hepatic creatinine production)
• eGFR: Unreliable in cirrhosis (formulae overestimate function)
• Cystatin C: More accurate than creatinine in cirrhosis (PMID: 27343606)

Electrolytes:

• Sodium: Low (dilutional hyponatraemia, often 125-132 mmol/L)
• Potassium: Variable (may be low from diuretics or high from AKI)
• Chloride: Often low

Liver Function:

• Bilirubin: Elevated (often >100 umol/L in HRS)
• ALT/AST: Variable (often only mildly elevated in chronic cirrhosis)
• ALP/GGT: Variable
• Albumin: Low (<30 g/L)
• INR: Prolonged (>1.5)
• Ammonia: Elevated (encephalopathy correlation is imperfect)

Full Blood Count:

• Haemoglobin: Often low (chronic disease, hypersplenism, GI bleeding)
• WCC: Variable (may be low from hypersplenism, elevated in infection)
• Platelets: Low (hypersplenism, typically 50-100 × 10^9/L)

Coagulation:

• INR: Prolonged
• APTT: Prolonged
• Fibrinogen: Variable (acute phase reactant may be normal)
• Note: Global coagulation in cirrhosis is rebalanced - INR underestimates bleeding risk in some, overestimates in others

Inflammatory Markers:

• CRP: May be elevated (infection, inflammation)
• Procalcitonin: Less reliable in cirrhosis but may help identify bacterial infection (PMID: 30084381)

Specific Tests:

Urine Tests (CRITICAL for HRS diagnosis):

Fractional Excretion of Sodium (FENa):

FENa = (Urine Na × Plasma Cr) / (Plasma Na × Urine Cr) × 100

• HRS: <1% (avid sodium retention despite AKI)
• Limitation: Unreliable if recent diuretics - use FEUrea instead

Fractional Excretion of Urea (FEUrea):

FEUrea = (Urine Urea × Plasma Cr) / (Plasma Urea × Urine Cr) × 100

• HRS: <35%
• Advantage: Less affected by diuretics

Ascitic Fluid Analysis

Mandatory in all cirrhotic patients with AKI to exclude SBP:

• Cell count: WCC >250 cells/mm³ (PMN predominant) = SBP
• Culture: Inoculate blood culture bottles at bedside
• Protein: Low (<15 g/L) = high risk of SBP
• Albumin: Calculate SAAG (serum-ascites albumin gradient)

SAAG (Serum-Ascites Albumin Gradient):

• SAAG ≥11 g/L = portal hypertension (cirrhosis, CHF, Budd-Chiari)
• SAAG <11 g/L = non-portal causes (malignancy, TB, nephrotic syndrome)

Imaging

Renal Ultrasound:

• Mandatory to exclude obstruction
• Findings in HRS:
  • Normal kidney size and echogenicity (or slightly small if chronic)
  • No hydronephrosis
  • Increased renal resistive index (>0.70) on Doppler
  • Reduced cortical perfusion
• Note: Presence of ascites can make imaging technically challenging

Abdominal Ultrasound/CT:

• Assess for: Hepatocellular carcinoma (contraindication to transplant if advanced)
• Portal vein patency
• Splenomegaly (portal hypertension)
• Ascites quantification

Hepatic Doppler:

• Portal vein flow (hepatofugal flow indicates advanced portal hypertension)
• TIPS patency if previously placed

Echocardiography:

• Assess for cirrhotic cardiomyopathy
• Pre-TIPS assessment
• Pre-transplant evaluation
• Look for: Elevated PASP, diastolic dysfunction, reduced contractile reserve

Physiological Monitoring

Non-Invasive Monitoring:

• Continuous ECG: Arrhythmias (electrolyte disturbances, cardiomyopathy)
• SpO2: Hepatopulmonary syndrome, pulmonary oedema
• NIBP or arterial line: MAP target 65-75 mmHg (higher with vasoconstrictors)
• Respiratory rate
• Temperature

Invasive Monitoring:

• Arterial line: Essential if on vasoconstrictors
• Central venous catheter: Drug administration, CVP trending (less useful in cirrhosis - CVP may not reflect intravascular volume)
• Urinary catheter: Hourly urine output
• Cardiac output monitoring: Consider if unclear fluid responsiveness

Organ-Specific Monitoring:

• Urine output: Target >0.5 mL/kg/hr
• Daily creatinine trend
• Daily electrolytes (sodium, potassium)
• Hepatic encephalopathy grade (q4h)
• Ammonia level (correlates poorly with encephalopathy)

---

ICU Management

This is the core clinical section

Initial Resuscitation (First Hour)

A - Airway:

• Assessment: Level of consciousness (hepatic encephalopathy grade)
• Intervention: Intubation indicated for Grade 4 encephalopathy, respiratory failure, or aspiration risk
• RSI considerations:
  • Rapid sequence due to aspiration risk (ascites, gastroparesis)
  • "Drug choice: Propofol (reduced dose - impaired metabolism), ketamine (avoid if raised ICP)"
  • "Paralysis: Rocuronium (cisatracurium if prolonged paralysis expected - organ-independent elimination)"
  • Avoid succinylcholine if hyperkalaemic

B - Breathing:

• Oxygen therapy: Target SpO2 92-96%
• Assess for: Hepatic hydrothorax (right-sided in 80%), pulmonary oedema
• Avoid excessive PEEP if haemodynamically unstable
• Hepatopulmonary syndrome: May require high FiO2

C - Circulation:

Volume Assessment in Cirrhosis (challenging):

• Peripheral oedema and ascites indicate total body fluid OVERLOAD
• BUT: Effective arterial blood volume is DEPLETED
• JVP may be low despite total body fluid excess
• CVP is an unreliable indicator

Initial Fluid Strategy:

• Albumin 20-25%: 1 g/kg/day for 2 days (maximum 100 g/day)
• If no response after 48 hours = HRS confirmed
• If improvement = prerenal AKI, continue albumin
• Avoid crystalloid (low oncotic pressure, leaks to third space)
• Avoid excessive volume (worsens ascites, hepatic hydrothorax)

Vasopressor Initiation (if no response to albumin OR haemodynamically unstable):

Australian Practice - Noradrenaline First-Line:

• Indication: MAP <65 mmHg despite albumin, or HRS-AKI diagnosed
• Starting dose: 0.5-1 mcg/min (0.01 mcg/kg/min)
• Target: MAP 65-75 mmHg (higher targets may improve renal perfusion but increase cardiac risk)
• Titration: Increase by 0.5-1 mcg/min every 15-30 min
• Maximum: 3 mcg/kg/min (consider escalation if higher doses needed)

If Terlipressin Used:

• Indication: HRS-AKI with no contraindications
• Dosing: 1 mg IV q4-6h OR 2 mg IV q12h
• Increase to 2 mg q4-6h if no response at 48-72h
• Combine with albumin 20-40 g/day
• Monitor for ischaemic complications

D - Disability:

• GCS/encephalopathy grade monitoring
• Lactulose: 20-30 mL PO/NG q6-8h, titrate to 2-3 soft stools/day
• Rifaximin: 550 mg PO BD (if recurrent encephalopathy, after SBP excluded)
• Glucose control: Target 6-10 mmol/L (impaired gluconeogenesis - hypoglycaemia risk)

E - Everything Else:

• Temperature management: Normothermia (impaired thermoregulation)
• Source control: Identify and treat precipitant

Identify and Treat Precipitants

Spontaneous Bacterial Peritonitis (SBP):

• Diagnosis: Ascitic fluid PMN >250 cells/mm³
• Treatment:
  • "Empiric antibiotics: Ceftriaxone 2g IV daily OR Cefotaxime 2g IV q8h"
  • "Albumin: 1.5 g/kg at diagnosis + 1 g/kg on day 3 (reduces HRS and mortality - PMID: 10403001)"
  • "Duration: 5-7 days (guided by repeat paracentesis if needed)"
• Prevention after episode: Norfloxacin 400 mg daily OR TMP-SMX DS daily

Gastrointestinal Bleeding:

• Resuscitation: Restrictive transfusion (Hb target 70-80 g/L)
• Proton pump inhibitor: Pantoprazole 80 mg IV bolus then 8 mg/h
• Terlipressin 2 mg IV then 1 mg q4-6h (for variceal bleeding)
• Octreotide 50 mcg bolus then 25-50 mcg/h infusion
• Urgent endoscopy: Within 12 hours
• Antibiotic prophylaxis: Ceftriaxone 1g IV daily for 7 days

Large Volume Paracentesis without Albumin:

• Prevention: Always give albumin 6-8 g per litre removed if >5L drained
• Treatment of HRS: Standard HRS protocol

Nephrotoxic Drug Exposure:

• NSAIDs: Cease immediately
• Aminoglycosides: Avoid, use alternatives
• Contrast: Usually avoid; if essential, use iso-osmolar contrast with volume expansion

Definitive Management (First 24-72 Hours)

Vasoconstrictor + Albumin Therapy:

Protocol (Noradrenaline - Australian Standard):

1. Albumin 20-25%: 1 g/kg/day (max 100g) for initial 2 days, then 20-40g/day
2. Noradrenaline: Start at 0.5-1 mcg/min, titrate to MAP 65-75 mmHg
3. Duration: Continue for minimum 7-14 days
4. Response assessment:
   • Check creatinine at 48-72h
   • "Full response": Creatinine returns to <133 umol/L (or within 26 umol/L of baseline)
   • "Partial response": Creatinine decreases by ≥50% but remains >133 umol/L
   • "Non-response": <50% decrease in creatinine at 14 days
5. If response: Continue until creatinine stable, wean vasoconstrictor slowly
6. If no response at 14 days: Consider futility, TIPS, or escalation to RRT as bridge to transplant

Protocol (Terlipressin - if used):

1. Albumin: As above
2. Terlipressin: Start 1 mg IV q4-6h
3. Increase to 2 mg q4-6h if no response at 48-72h
4. Maximum: 12 mg/day
5. Duration: Continue until response or max 14 days
6. Contraindications: IHD, PVD, CVD, respiratory failure

Response Rates (PMID: 33657293, 29753639):

• Complete response: 20-35%
• Partial response: 20-30%
• Non-response: 40-50%
• HRS recurrence after initial response: 15-25%

TIPS (Transjugular Intrahepatic Portosystemic Shunt)

Mechanism: Decompresses portal system, reduces splanchnic pooling, increases effective arterial blood volume.

Indication in HRS:

• HRS-CKD (Type 2) with refractory ascites
• HRS-AKI non-responsive to vasoconstrictors (salvage)
• Bridge to transplant in selected patients

Contraindications:

• Absolute:
  • Child-Pugh >13, MELD >18 (high procedural mortality)
  • Severe hepatic encephalopathy (Grade 3-4)
  • Hepatocellular carcinoma (unless meeting transplant criteria)
  • Portal vein thrombosis (complete)
  • Severe tricuspid regurgitation
  • Right heart failure
• Relative:
  • Recurrent encephalopathy
  • Severe coagulopathy
  • Sepsis

Evidence (PMID: 29753639):

• Small studies suggest benefit in HRS-CKD
• Limited data for HRS-AKI
• Not first-line therapy

Renal Replacement Therapy

RRT in HRS - Key Principles:

• RRT does NOT treat underlying HRS pathophysiology
• HRS is NOT an indication for RRT per se
• RRT is used as BRIDGE TO TRANSPLANT, not definitive treatment
• Without transplant candidacy, RRT in HRS is generally futile

Indications for RRT in HRS (same as general AKI):

• Refractory hyperkalaemia (K+ >6.5 mmol/L despite medical therapy)
• Refractory metabolic acidosis (pH <7.1-7.2)
• Refractory pulmonary oedema
• Uraemic complications (encephalopathy worsening, pericarditis, bleeding)
• Severe azotaemia (urea >35-40 mmol/L with symptoms)

Modality Selection:

• CRRT preferred: Haemodynamic instability common in cirrhosis
• Anticoagulation: Regional citrate preferred (citrate metabolism may be impaired in severe liver dysfunction - monitor for accumulation)
• Citrate caution: If total Ca:ionised Ca ratio >2.5, consider citrate accumulation

Technical Considerations in Cirrhosis:

• Coagulopathy: May use no anticoagulation if INR prolonged
• Thrombocytopaenia: Filter clotting may be reduced
• Access: May be challenging due to coagulopathy
• Fluid removal: Caution with aggressive ultrafiltration (worsen effective arterial volume)

Futility Considerations (PMID: 25046489):

• If patient is NOT a transplant candidate, RRT in HRS is not recommended
• Median survival with RRT but without transplant: <3 months
• Shared decision-making with patient/family essential
• Indigenous health considerations: Ensure culturally safe discussions about prognosis and treatment limitations

Liver Transplantation

The Only Definitive Treatment for HRS:

Indications for Transplant Referral (PMID: 29753639):

• All patients with HRS-AKI should be urgently assessed for transplant
• MELD score incorporates renal function, giving priority to HRS patients
• Combined liver-kidney transplant (CLKT) criteria (varies by region):
  • Dialysis-dependent for >6-12 weeks
  • eGFR <25-30 mL/min for >6-12 weeks
  • Structural kidney disease (CKD stage 4-5)

Contraindications to Liver Transplantation:

• Active alcohol/substance use (typically require 6 months abstinence in Australia)
• Uncontrolled sepsis
• Advanced hepatocellular carcinoma (beyond Milan criteria)
• Severe cardiopulmonary disease
• Active extrahepatic malignancy
• Non-compliance with medical therapy
• Lack of adequate social support

Australian Liver Transplant Centres:

• NSW: Royal Prince Alfred Hospital, Sydney
• Victoria: Austin Hospital, Melbourne
• Queensland: Princess Alexandra Hospital, Brisbane
• South Australia: Flinders Medical Centre, Adelaide
• Western Australia: Sir Charles Gairdner Hospital, Perth
• New Zealand: Auckland City Hospital

MELD Score and Allocation:

• Australian system uses MELD for allocation priority
• MELD score updated every 7 days while listed
• HRS with rising creatinine rapidly increases MELD priority
• Exception points may be granted for specific indications

Post-Transplant Renal Outcomes (PMID: 15084697):

• 50-75% of HRS patients have recovery of renal function after liver transplant alone
• Better outcomes if HRS duration <12 weeks and pre-transplant RRT <4-8 weeks
• Combined liver-kidney transplant if RRT >8-12 weeks (varies by centre)
• Long-term renal function often impaired due to calcineurin inhibitor nephrotoxicity

Indigenous Health Considerations

Aboriginal and Torres Strait Islander Peoples:

Epidemiology (PMID: 24995628):

• 2-3x higher rates of chronic liver disease
• Higher prevalence of hepatitis B (especially Northern Territory)
• Higher alcohol-related liver disease rates
• Younger age at presentation with decompensated cirrhosis
• Higher rates of diabetes and metabolic risk factors

Barriers to Care:

• Geographic: Remote location, distance from tertiary centres and transplant services
• Cultural: Different health beliefs, importance of family/community in decision-making
• Socioeconomic: Lower rates of health insurance, transport difficulties
• Systemic: Lower referral rates to transplant services

Best Practice Recommendations:

1. Early Referral: Lower threshold for transplant assessment
2. Cultural Safety:
   • Involve Aboriginal Health Workers (AHW) or Aboriginal Liaison Officers (ALO)
   • Engage with family and community in decision-making
   • Recognise importance of Country and connection to land
3. Communication:
   • Use interpreter services
   • Allow time for family consultation
   • Explain medical concepts in culturally appropriate ways
4. Holistic Care: Address social determinants alongside medical management
5. Telehealth: Use telemedicine for remote consultations with hepatology/transplant teams
6. Retrieval: Early engagement with retrieval services (RFDS, state retrieval services) if transfer required

Māori Health (New Zealand):

• Similar disparities in liver disease rates
• Importance of whānau (extended family) involvement
• Respect for tikanga (customs) in healthcare delivery
• Māori Health Workers involvement in care planning
• Consider Kaupapa Māori health approaches

Ongoing ICU Care (Beyond 48 Hours)

Daily Management:

• Daily creatinine and electrolytes
• Daily assessment of encephalopathy grade
• Vasoconstrictor titration to MAP targets
• Albumin as indicated
• Lactulose titration
• VTE prophylaxis (mechanical if coagulopathic; LMWH if INR <2.5 and platelets >50)
• Stress ulcer prophylaxis: PPI (increased SBP risk - monitor)
• Nutritional support: Enteral nutrition preferred, 30-35 kcal/kg/day, protein 1.2-1.5 g/kg/day (not restricted unless severe encephalopathy)

Response Monitoring:

• Creatinine trend (daily)
• Urine output (hourly)
• Sodium (daily - hyponatraemia common)
• Signs of vasoconstrictor toxicity (ischaemia, arrhythmias)

Weaning Vasoconstrictors (in responders):

• Once creatinine stable/improving, wean slowly over 48-72h
• Monitor for HRS recurrence
• Maintain albumin support

Family Communication:

• Early discussion of prognosis
• Transplant candidacy assessment
• Goals of care discussion
• Involvement of palliative care if not transplant candidate
• Cultural considerations in end-of-life discussions

---

Monitoring & Complications

ICU-Specific Monitoring

Daily Parameters:

• Vital signs: Hourly (MAP target 65-75 mmHg on vasoconstrictors)
• Fluid balance: Daily assessment (complex - ascites, peripheral oedema vs intravascular volume)
• Urine output: Hourly (target >0.5 mL/kg/h)
• Laboratory: Daily creatinine, electrolytes, LFTs, albumin, INR
• ABG: As needed for acid-base status

Trend Monitoring:

• Creatinine trajectory: Most important marker of response
• Sodium: Progressive hyponatraemia indicates poor prognosis
• MELD score: Daily recalculation
• Encephalopathy grade: q4-6h

Safety Monitoring:

• ECG: Continuous (vasoconstrictor-induced ischaemia, arrhythmias)
• Peripheral perfusion: Digital/limb ischaemia with vasoconstrictors
• Signs of GI ischaemia: Abdominal pain, bloody stools

Complications

Complications of HRS Itself:

1. Progressive Renal Failure:

• Incidence: 50-60% non-responders
• Management: RRT if transplant candidate
• Prognosis: Poor without transplant

2. Hepatic Encephalopathy:

• Incidence: Worsens in 30-50% during HRS
• Prevention: Lactulose, rifaximin
• Management: Identify precipitants (infection, GI bleed, electrolyte disturbance)

3. Coagulopathy and Bleeding:

• INR prolongation universal
• Paradoxically, may also have thrombotic tendency (rebalanced haemostasis)
• Management: Target-directed transfusion if bleeding; avoid excessive FFP

4. Infections (especially SBP):

• High vigilance for new infection
• Consider antibiotic prophylaxis
• Early diagnostic paracentesis if clinical deterioration

Complications of Treatment:

Vasoconstrictor-Related:

• Cardiovascular: Myocardial ischaemia (5-10%), arrhythmias (5%)
• Peripheral: Digital ischaemia, skin necrosis (2-5%)
• GI: Mesenteric ischaemia (<2%), abdominal pain
• Respiratory: ARDS, respiratory failure (11% with terlipressin in CONFIRM trial)
• Hyponatraemia: Especially with terlipressin (ADH effect)

RRT-Related (if initiated):

• Haemodynamic instability
• Citrate toxicity (if regional citrate anticoagulation)
• Catheter-related complications
• Hypothermia

ICU-Acquired Complications:

• Ventilator-associated pneumonia (if intubated)
• Central line-associated bloodstream infection
• ICU-acquired weakness
• Pressure injuries

---

Prognosis & Outcome Measures

Mortality

Short-Term Outcomes:

• HRS-AKI (Type 1) untreated: 80% mortality at 2 weeks
• HRS-AKI with vasoconstrictors: 50% mortality at 90 days
• HRS-CKD (Type 2) untreated: 50% mortality at 6 months
• ICU mortality for cirrhotic patients with HRS: 40-60%

Long-Term Outcomes:

• Post-liver transplant:
  • 1-year survival: 65-75%
  • 5-year survival: 50-60%
• Without transplant: Median survival 1-3 months

Comparison of Outcomes (PMID: 33657293, 29753639):

Morbidity

Functional Recovery:

• Renal function recovery post-transplant: 50-75%
• Complete renal recovery (return to baseline): 30-50%
• Progression to chronic dialysis post-transplant: 5-10%

Quality of Life:

• Post-transplant: Significant improvement in QoL measures
• Without transplant: Progressive decline with repeated decompensations

Prognostic Factors

Good Prognostic Factors:

• Lower MELD score (<30)
• Response to vasoconstrictors at 72 hours
• Lower baseline serum creatinine
• Absence of SBP or other infection
• Younger age
• Lower bilirubin
• Transplant candidacy

Poor Prognostic Factors:

• MELD score >30
• Serum bilirubin >171 umol/L (10 mg/dL)
• Non-response to vasoconstrictors at 14 days
• Active infection
• Hepatocellular carcinoma (beyond Milan criteria)
• Cardiac dysfunction
• Age >65 years
• Need for RRT before transplant
• Not a transplant candidate

Scoring Systems

MELD Score:

• Best validated prognostic score in HRS
• Incorporates creatinine, bilirubin, INR
• Higher score = worse prognosis BUT higher transplant priority
• MELD-Na (incorporating sodium) may improve prognostication

Child-Pugh Score:

• Less useful than MELD for transplant allocation
• Still useful for procedural risk assessment (e.g., TIPS)

CLIF-C ACLF Score:

• For acute-on-chronic liver failure
• Incorporates organ failures, age, WBC
• Better predicts short-term mortality than MELD alone

Response to Vasoconstrictors:

• Best predictor of short-term survival without transplant
• Non-responders at 14 days have very poor prognosis
• Consider goals of care discussion if non-response

Australian/NZ Outcome Data

ANZICS CORE/APD Data:

• Cirrhotic ICU patients: In-hospital mortality 30-40%
• Cirrhotic ICU patients with RRT: In-hospital mortality 50-60%
• Aboriginal and Torres Strait Islander patients: Similar acute outcomes but lower transplant rates

Indigenous Health Outcomes:

• Lower rates of liver transplant listing
• Similar short-term mortality once listed
• Higher attrition from waitlist
• Ongoing efforts to improve equity in transplant access

---

SAQ Practice (Full Exam-Level)

SAQ 1: HRS Diagnosis and Management

Time Allocation: 10 minutes
Total Marks: 20

Stem:

A 52-year-old male with known alcoholic cirrhosis (Child-Pugh C, MELD 28) is admitted to ICU from the medical ward. He presented 4 days ago with increasing abdominal distension and was diagnosed with tense ascites. He underwent therapeutic paracentesis 3 days ago with 8 litres removed; no albumin was given.

Current observations:

• HR: 105 bpm
• BP: 88/52 mmHg
• RR: 22/min
• SpO2: 94% on 4L O2
• Temperature: 37.8°C
• Urine output: 180 mL over 12 hours

Investigations:

Bloods:

• Na: 126 mmol/L, K: 5.2 mmol/L
• Urea: 28.5 mmol/L
• Creatinine: 312 umol/L (baseline 85 umol/L 3 weeks ago)
• Bilirubin: 185 umol/L
• Albumin: 22 g/L
• INR: 2.1

Urine:

• Sodium: 8 mmol/L
• Osmolality: 520 mOsm/kg
• Microscopy: Occasional hyaline casts, no RBCs, no WBCs

Ascitic fluid (from diagnostic tap):

• WCC: 380 cells/mm³ (85% PMN)
• Culture: Pending

---

Question 1.1 (8 marks)

What is your diagnosis? Outline the key clinical and laboratory features that support this diagnosis.

Question 1.2 (6 marks)

Describe your management priorities in the first 24 hours.

Question 1.3 (6 marks)

The patient receives appropriate treatment for 72 hours but serum creatinine remains elevated at 285 umol/L. Discuss the options for escalation of therapy and factors that would influence your decision-making.

---

Model Answer

Question 1.1 (8 marks total)

Primary Diagnosis: Hepatorenal Syndrome - Acute Kidney Injury (HRS-AKI, formerly Type 1), precipitated by Spontaneous Bacterial Peritonitis (SBP) and large volume paracentesis without albumin replacement. (2 marks)

Supporting Clinical Features (3 marks):

• Known decompensated alcoholic cirrhosis with ascites (Child-Pugh C, MELD 28)
• Clear precipitants: Large volume paracentesis (8L) without albumin replacement + SBP (ascitic PMN >250/mm³)
• Hypotension (MAP ~64 mmHg) consistent with circulatory dysfunction
• Oliguria (<0.5 mL/kg/hr) indicating renal hypoperfusion

Supporting Laboratory Features (3 marks):

• AKI: Creatinine 312 umol/L (>3.5x baseline of 85), meeting ICA-AKI Stage 3
• Preserved tubular function (pathognomonic for HRS):
  • Urine sodium <10 mmol/L (avid sodium retention despite AKI)
  • Urine osmolality >500 mOsm/kg (concentrated urine)
  • Bland urinary sediment (no casts of ATN)
• Hyponatraemia (Na 126) indicating dilutional effect from ADH activation
• Elevated bilirubin and coagulopathy consistent with severe liver dysfunction
• SBP confirmed: Ascitic PMN 380/mm³ with >250/mm³ threshold and PMN predominance

Alternative Diagnoses to Consider (but less likely):

• ATN: Would expect urine Na >40 mmol/L, muddy brown casts
• Prerenal AKI: Possible component, but lack of response to albumin trial would confirm HRS
• Obstruction: Excluded by renal ultrasound (not mentioned but should be performed)

---

Question 1.2 (6 marks total)

Immediate Priorities (First 24 Hours):

1. Treat SBP (2 marks):

• Empiric antibiotics: Ceftriaxone 2g IV daily (or cefotaxime 2g IV q8h)
• Albumin for SBP: 1.5 g/kg IV at diagnosis, 1 g/kg on day 3 (reduces HRS development and mortality - Sort trial, PMID: 10403001)
• Duration: 5-7 days

2. Volume Expansion and Circulatory Support (2 marks):

• Albumin 20-25%: 1 g/kg/day (max 100g/day) for 2 days
• If no improvement or MAP remains <65 mmHg, initiate vasoconstrictors
• Noradrenaline: Start 0.5-1 mcg/min, titrate to MAP 65-75 mmHg (Australian practice)
• Alternative: Terlipressin 1mg IV q4-6h if available and no contraindications

3. Supportive Care (1 mark):

• Cease diuretics (spironolactone, furosemide)
• Cease any nephrotoxins (NSAIDs - confirm none given)
• Hepatic encephalopathy management: Lactulose 20-30 mL q6-8h
• VTE prophylaxis: Mechanical (coagulopathic)

4. Monitoring and Investigations (1 mark):

• Arterial line for continuous BP monitoring
• Hourly urine output
• Daily creatinine, electrolytes
• Renal ultrasound to exclude obstruction
• Serial ammonia if encephalopathy worsens
• Urgent hepatology/transplant referral

---

Question 1.3 (6 marks total)

Partial Response Assessment (1 mark):

• Creatinine 285 umol/L (decreased from 312) = 8.7% reduction
• This represents <50% reduction = non-response at 72 hours
• However, some improvement suggests potential for further response

Escalation Options (3 marks):

1. Optimise Medical Therapy:

• If on noradrenaline: Increase dose (up to 0.3-0.5 mcg/kg/min if tolerated) to achieve higher MAP targets (75-85 mmHg)
• Ensure adequate albumin supplementation (20-40 g/day ongoing)
• If terlipressin available: Consider switch or addition (1-2 mg IV q4-6h)
• Continue therapy for full 14-day trial before declaring treatment failure

2. TIPS (Transjugular Intrahepatic Portosystemic Shunt):

• Consider if: Child-Pugh <13, MELD <18, no severe encephalopathy
• Contraindicated in this patient: MELD 28 (>18), high procedural mortality
• Unlikely to be appropriate option here

3. Renal Replacement Therapy:

• NOT indicated for HRS per se, only for standard indications (hyperkalaemia, acidosis, overload, uraemia)
• Consider only if patient is a TRANSPLANT CANDIDATE (bridge to transplant)
• Without transplant candidacy, RRT in HRS is futile

Factors Influencing Decision-Making (2 marks):

Transplant Candidacy:

• Essential question: Is this patient a transplant candidate?
• Must have 6-month alcohol abstinence (Australian requirement)
• Requires transplant team assessment
• If candidate: Continue aggressive therapy including RRT as bridge
• If not candidate: Goals of care discussion, consider treatment limitations

Prognostic Factors:

• MELD 28: High score - poor prognosis without transplant but high priority if listed
• Bilirubin 185 umol/L: Poor prognostic marker
• Partial response at 72 h: Slightly encouraging, may continue to improve
• Age, comorbidities, social support for transplant

Communication and Shared Decision-Making (included in above):

• Involve patient and family in discussions about prognosis
• Consider palliative care involvement if not transplant candidate
• Cultural considerations (Aboriginal Health Worker if applicable)
• Clear documentation of goals of care

---

Common Mistakes:

• Not recognising SBP as the precipitant and failing to treat adequately
• Using crystalloid instead of albumin for volume expansion
• Delaying vasoconstrictor therapy while "waiting to see" if albumin works
• Initiating RRT without transplant assessment
• Not considering TIPS contraindications (MELD >18)

Examiner Comments:

• Strong candidates discuss both the pathophysiology (why LVP without albumin + SBP precipitates HRS) and management
• Expected to mention Australian practice preference for noradrenaline
• Must discuss transplant candidacy - this is the key determinant of treatment escalation

---

SAQ 2: Pathophysiology and Differential Diagnosis

Time Allocation: 10 minutes
Total Marks: 20

Stem:

A 61-year-old female with NASH cirrhosis is admitted to ICU with hepatic encephalopathy (Grade 3), tense ascites, and acute kidney injury (creatinine 245 umol/L, baseline 72 umol/L). She received ceftriaxone for presumed SBP (subsequently excluded) and albumin 1 g/kg/day for 2 days with no improvement in creatinine.

Urine Investigations:

• Urine sodium: 58 mmol/L
• Urine osmolality: 285 mOsm/kg
• Urinalysis: 2+ blood, protein trace, granular casts present

---

Question 2.1 (8 marks)

The admitting team diagnosed hepatorenal syndrome (HRS). Do you agree with this diagnosis? Justify your answer with reference to the diagnostic criteria and urine findings.

Question 2.2 (6 marks)

Outline the pathophysiological differences between hepatorenal syndrome and acute tubular necrosis in a patient with cirrhosis.

Question 2.3 (6 marks)

Describe your approach to management, acknowledging the diagnostic uncertainty.

---

Model Answer

Question 2.1 (8 marks total)

No, I do not agree with the diagnosis of HRS. (2 marks)

This patient's urine findings are inconsistent with HRS and suggest Acute Tubular Necrosis (ATN) as the more likely diagnosis.

ICA 2015 Diagnostic Criteria for HRS (2 marks):

1. Cirrhosis with ascites - PRESENT
2. AKI per ICA-AKI criteria - PRESENT (creatinine rise >3x baseline)
3. No response to 2 days albumin - PRESENT
4. Absence of shock - Need to confirm (not stated)
5. No current nephrotoxin use - Not stated, but ceftriaxone generally not nephrotoxic
6. No macroscopic signs of structural kidney injury:
   • Proteinuria <500 mg/day - PRESENT (trace only)
   • Microhaematuria <50 RBCs/HPF - POSSIBLY VIOLATED (2+ blood on dipstick)
   • Normal renal ultrasound - Not stated

Urine Findings Inconsistent with HRS (2 marks):

Interpretation (2 marks):

• Urine sodium 58 mmol/L indicates impaired tubular sodium reabsorption (tubular dysfunction)
• Urine osmolality 285 mOsm/kg indicates loss of concentrating ability (tubular dysfunction)
• Granular casts indicate tubular injury
• Haematuria (2+) is unusual in HRS (should have bland sediment)

Most Likely Diagnosis: ATN, possibly from preceding hypotension, sepsis, or other insult. Alternative considerations include acute interstitial nephritis (from ceftriaxone or prior medications) or glomerulonephritis (given haematuria).

---

Question 2.2 (6 marks total)

Pathophysiological Differences:

Hepatorenal Syndrome (3 marks):

• Nature: Functional renal failure - kidneys are structurally normal
• Primary Mechanism:
  • Splanchnic vasodilation (nitric oxide, bacterial translocation)
  • Arterial underfilling triggers RAAS/SNS activation
  • Intense renal afferent arteriole VASOCONSTRICTION
  • Reduced renal blood flow and GFR
• Tubular Function: PRESERVED
  • Avid sodium reabsorption (urine Na <10 mmol/L)
  • Intact concentrating ability (urine osmolality >500 mOsm/kg)
  • No tubular cell injury (bland sediment)
• Reversibility:
  • Functional - kidneys recover if liver function restored (transplant)
  • HRS kidneys function normally when transplanted into non-cirrhotic recipients
• Key Concept: The kidney is responding appropriately to perceived volume depletion

Acute Tubular Necrosis (3 marks):

• Nature: Structural renal injury - tubular epithelial cell damage
• Primary Mechanism:
  • "Ischaemic ATN: Prolonged hypoperfusion beyond autoregulatory threshold"
  • "Nephrotoxic ATN: Direct tubular toxicity (drugs, contrast, pigments)"
  • ATP depletion, loss of cell polarity, apoptosis, necrosis
• Tubular Function: IMPAIRED
  • Loss of sodium reabsorption (urine Na >40 mmol/L)
  • Loss of concentrating ability (urine osmolality <350 mOsm/kg)
  • Tubular debris (muddy brown casts)
• Reversibility:
  • Typically recovers in 2-4 weeks with supportive care
  • Does NOT specifically require liver transplantation for renal recovery
• Key Concept: The kidney has structural injury and cannot perform normal tubular functions

Important Clinical Distinction:

• HRS will NOT improve with volume expansion or vasoconstrictors alone if severe (needs transplant)
• ATN will typically recover with supportive care and time
• Treatment strategies differ: Vasoconstrictors help HRS but not ATN
• In practice, both can coexist - prolonged HRS can lead to superimposed ATN

---

Question 2.3 (6 marks total)

Management Approach with Diagnostic Uncertainty:

1. Further Investigations (2 marks):

• Renal ultrasound: Exclude obstruction, assess kidney size
• Urine microscopy: Repeat with fresh sample, look for specific casts
• FEUrea: Calculate (less affected by recent diuretics than FENa)
  • FEUrea = (Urine Urea × Plasma Cr) / (Plasma Urea × Urine Cr) × 100
  • <35% suggests prerenal/HRS, >50% suggests ATN
• Review medication history: Any potential nephrotoxins (NSAIDs, aminoglycosides, contrast)
• Check for preceding hypotensive episodes on ward (may explain ATN)
• Consider cryoglobulins, ANA, ANCA if glomerulonephritis suspected (given haematuria)

2. Supportive Management (2 marks):

• Continue albumin support (20-40 g/day)
• Avoid nephrotoxins
• Optimise haemodynamics (MAP >65 mmHg)
• Treat hepatic encephalopathy (lactulose, rifaximin)
• Nutritional support
• VTE prophylaxis

3. Trial of Therapy (1 mark):

• Despite urine findings suggesting ATN, a trial of vasoconstrictor therapy may still be considered
• If patient is transplant candidate and ATN component present, will still need bridge therapy
• Monitor response: Improvement suggests HRS component; no improvement suggests ATN predominant
• Duration: 7-14 days for adequate trial

4. Transplant Assessment (1 mark):

• Regardless of diagnosis (HRS vs ATN), patient needs urgent transplant evaluation
• NASH cirrhosis with decompensation warrants listing consideration
• If ATN: May recover before transplant, but still evaluate
• If HRS with ATN: Worse prognosis, may need combined liver-kidney transplant
• Multidisciplinary discussion (ICU, hepatology, transplant, nephrology)

---

Common Mistakes:

• Diagnosing HRS without critically evaluating urine findings
• Not recognising the differences in urine biochemistry between HRS and ATN
• Failing to consider ATN as a common alternative diagnosis in cirrhotic patients
• Assuming all AKI in cirrhosis is HRS

Examiner Comments:

• Candidates should recognise that urine sodium >40 mmol/L and low osmolality are NOT consistent with HRS
• Pathophysiology explanation should clearly distinguish functional vs structural renal failure
• Pragmatic approach acknowledging diagnostic uncertainty is appropriate

---

Viva Scenarios

Viva Scenario 1: Pathophysiology and Management

Stem: "A 58-year-old man with decompensated alcoholic cirrhosis has developed AKI with a creatinine of 295 umol/L (baseline 80). He has tense ascites and hepatic encephalopathy Grade 2. His urine sodium is 5 mmol/L and urinalysis shows only hyaline casts."

Duration: 12 minutes (2 min reading + 10 min discussion)

---

Opening Question:

"What is your initial assessment of this patient?"

Expected Answer (2-3 minutes):

This patient likely has hepatorenal syndrome (HRS-AKI) based on:

Clinical Features:

• Decompensated alcoholic cirrhosis with ascites and encephalopathy
• Significant AKI (creatinine nearly 4x baseline)
• Classic HRS urine findings:
  • Urine sodium <10 mmol/L (preserved tubular sodium reabsorption)
  • Bland sediment (only hyaline casts - no ATN)

Severity Assessment:

• Creatinine >2x baseline = ICA-AKI Stage 2 or 3
• Encephalopathy indicates advanced liver disease
• Need to calculate MELD score for prognosis and transplant priority

Immediate Concerns:

• Identify precipitant (SBP, recent LVP, GI bleed, nephrotoxins)
• Assess haemodynamic status (likely hypotensive, hyperdynamic circulation)
• Volume status (intravascular depletion despite total body fluid overload)

---

Follow-up Question 1 (2-3 minutes):

"Explain the pathophysiology of hepatorenal syndrome to me."

Expected Answer:

The Arterial Underfilling Hypothesis:

HRS is a functional renal failure caused by intense renal vasoconstriction secondary to systemic circulatory dysfunction in advanced liver disease.

Cascade of Events:

1. Portal Hypertension leads to increased splanchnic blood flow and vasodilation

   • Mediators: Nitric oxide (main), carbon monoxide, endogenous cannabinoids
   • Bacterial translocation from gut increases NO production

2. Splanchnic Vasodilation causes pooling of blood in mesenteric circulation

   • Effective arterial blood volume decreases
   • Despite normal or high cardiac output, organs perceive "underfilling"

3. Neurohormonal Activation in response to perceived hypovolaemia:

   • Renin-Angiotensin-Aldosterone System (RAAS): Intense activation
   • Sympathetic Nervous System: Increased renal sympathetic activity
   • Arginine Vasopressin: Non-osmotic release

4. Renal Vasoconstriction develops when compensatory mechanisms overwhelm

   • Intense afferent arteriole constriction
   • Decreased renal blood flow despite adequate cardiac output
   • Reduced GFR

5. Protective Mechanisms Fail:

   • Normally, renal prostaglandins (PGE2, PGI2) counteract vasoconstriction
   • In HRS, vasoconstrictors overwhelm prostaglandin-mediated vasodilation
   • NSAIDs precipitate HRS by blocking this protective prostaglandin effect

Key Point: The kidneys are structurally normal. If transplanted into a non-cirrhotic recipient, they function normally. This confirms HRS is a haemodynamic disorder, not intrinsic renal disease.

---

Follow-up Question 2 (2-3 minutes):

"How would you manage this patient?"

Expected Answer:

Systematic Approach:

1. Identify and Treat Precipitants:

• Diagnostic paracentesis: Exclude SBP (PMN >250/mm³)
• If SBP present: Ceftriaxone 2g IV daily + albumin 1.5g/kg at diagnosis, 1g/kg day 3
• Review medications: Cease NSAIDs, aminoglycosides, diuretics
• Exclude GI bleeding

2. Volume Expansion:

• Albumin 20-25%: 1 g/kg/day for 2 days (max 100g/day)
• This is DIAGNOSTIC and THERAPEUTIC
• If creatinine improves = prerenal AKI
• If no improvement = HRS confirmed

3. Vasoconstrictors (if no response to albumin OR haemodynamically unstable):

Australian Practice - Noradrenaline First-Line:

• Start: 0.5-1 mcg/min
• Target: MAP 65-75 mmHg
• Advantages: Familiar, available, cheap, ICU experience
• Continue with albumin 20-40g/day

Alternative - Terlipressin:

• Dose: 1 mg IV q4-6h, increase to 2 mg q4-6h if no response at 48h
• Advantages: More splanchnic-specific vasoconstriction
• Disadvantages: Higher ischaemic risk (cardiac, peripheral, respiratory - CONFIRM trial)
• Not PBS-listed in Australia

4. Monitoring and Escalation:

• Daily creatinine, electrolytes
• Response assessment at 48-72h and 14 days
• If response: Continue until creatinine stable, wean slowly
• If no response: Goals of care discussion, TIPS consideration (if eligible), RRT if transplant candidate

5. Transplant Referral:

• Urgent hepatology/transplant team involvement
• MELD score calculation
• Assessment of transplant candidacy
• Combined liver-kidney transplant criteria if RRT >8-12 weeks

---

Follow-up Question 3 (2-3 minutes):

"What is the evidence for terlipressin compared to noradrenaline?"

Expected Answer:

Key Trials:

CONFIRM Trial (2021) (PMID: 33657293):

• Design: Phase 3, double-blind RCT, North America
• Population: 300 patients with HRS-AKI
• Intervention: Terlipressin + albumin vs placebo + albumin
• Primary Outcome: Verified HRS reversal (creatinine ≤133 umol/L)
• Results:
  • "HRS reversal: 32% terlipressin vs 17% placebo (p<0.001)"
  • 90-day mortality: No difference (51% vs 45%, NS)
• Safety: Respiratory failure 11% terlipressin vs 3% placebo
• Conclusion: Terlipressin improves renal function but NOT survival; significant respiratory adverse events

REVERSE Trial (2018) (PMID: 29753639):

• Design: Open-label RCT, India
• Population: 120 patients with HRS-AKI
• Intervention: Terlipressin vs noradrenaline (both with albumin)
• Primary Outcome: HRS reversal at 14 days
• Results:
  • "HRS reversal: 40% terlipressin vs 43% noradrenaline (NS)"
  • "Mortality: Similar (28-day and 90-day)"
  • "Adverse events: Similar (ischaemic events 5-8% both groups)"
• Conclusion: Noradrenaline is non-inferior to terlipressin

Clinical Implications:

• Both agents have similar efficacy (~40% response rate)
• Neither improves mortality without transplant
• Noradrenaline is reasonable first-line in Australian ICUs (familiarity, cost, availability)
• Terlipressin may have higher respiratory adverse effects
• Choice may depend on local practice, availability, and patient factors

---

Examiner's Expected Level:

Pass:

• Correctly identifies HRS based on clinical and urine findings
• Explains pathophysiology with appropriate depth (arterial underfilling, RAAS activation)
• Systematic management approach including precipitant treatment, albumin, vasoconstrictors
• Mentions transplant as definitive treatment
• Aware of evidence base (can name at least one trial)

Fail:

• Cannot distinguish HRS from ATN
• Poor understanding of pathophysiology
• Unsafe management (e.g., excessive crystalloid, ignoring SBP)
• Unaware that HRS requires transplant for definitive cure
• No knowledge of terlipressin vs noradrenaline evidence

---

Viva Scenario 2: Prognosis and Goals of Care

Stem: "A 68-year-old Aboriginal woman from a remote community in the Northern Territory has been in ICU for 10 days with HRS-AKI. She has received noradrenaline and albumin with no improvement in creatinine (now 385 umol/L). Her MELD score is 38. She has Child-Pugh C cirrhosis secondary to hepatitis B. She is on the liver transplant waitlist but no organ has become available. Her family is asking about 'what happens next'."

Duration: 12 minutes (2 min reading + 10 min discussion)

---

Opening Question:

"What are the prognostic factors in this case?"

Expected Answer (2-3 minutes):

Poor Prognostic Factors:

1. Non-response to vasoconstrictors at 10 days:

   • Standard trial is 14 days, but trajectory is concerning
   • Non-responders at 14 days have very poor prognosis without transplant
   • Some centres would consider treatment failure at 10-14 days

2. MELD Score 38:

   • Very high score indicates severe liver dysfunction
   • Paradoxically gives high transplant priority, BUT
   • High MELD also predicts higher waitlist and post-transplant mortality

3. Creatinine 385 umol/L:

   • Severe renal impairment
   • If RRT required pre-transplant for >8-12 weeks, likely needs combined liver-kidney transplant

4. Age 68 years:

   • Advanced age is a relative factor
   • Some centres have upper age limits (65-70)

5. Child-Pugh C Cirrhosis:

   • Most advanced cirrhosis, poorest baseline function

Potentially Positive Factors:

• On transplant waitlist (already assessed as candidate)
• Hepatitis B aetiology (potentially treatable to prevent recurrence)
• Still receiving organ support (treatment ongoing)

Prognosis Without Transplant:

• Median survival: 1-3 months
• 90-day mortality: >70%

---

Follow-up Question 1 (2-3 minutes):

"How would you approach the discussion with the family?"

Expected Answer:

Preparation:

• Review all clinical information
• Identify key family members/decision-makers (may be extensive in Aboriginal families)
• Involve Aboriginal Health Worker (AHW) or Aboriginal Liaison Officer (ALO)
• Organise interpreter if English not first language
• Allow adequate time, quiet room, seating for all family members
• Consider involvement of community Elders if appropriate

Meeting Structure:

1. Introduction and Rapport:

• Introduce yourself and team members
• Acknowledge Country if appropriate
• Allow family to introduce themselves
• Express appreciation for their presence

2. Explore Understanding:

• "Can you tell me what you understand about [patient's] illness?"
• Listen actively, correct misunderstandings gently

3. Share Information:

• Use clear, non-medical language
• "Her liver is very sick and cannot recover on its own"
• "The treatment we've been giving isn't helping her kidneys recover"
• "Without a new liver, she is very unlikely to survive"
• "We are waiting and hoping for a liver to become available"
• Check understanding: "Does that make sense? What questions do you have?"

4. Address Emotions:

• Allow time for grief, anger, questions
• "This must be very difficult news"
• Silence is okay - don't rush

5. Discuss Options and Goals:

• "If a liver doesn't become available soon, we need to think about what she would want"
• "We can continue treatment while we wait"
• "If things get worse, we may need to discuss whether intensive treatment is still helping her"
• Explore cultural/spiritual needs
• Connection to Country may be important - discuss possibility of repatriation if appropriate

6. Plan and Summarise:

• Document discussion
• Arrange follow-up meeting
• Provide contact information
• Involve social work, palliative care as appropriate

Cultural Considerations:

• In many Aboriginal communities, decision-making is collective
• May need to wait for extended family or Elders
• "Sorry business" and cultural obligations around death
• Importance of dying on Country (traditional lands)
• May need to involve men's and women's groups separately

---

Follow-up Question 2 (2-3 minutes):

"The patient's creatinine continues to rise and she is now requiring dialysis. Is there a role for ongoing RRT?"

Expected Answer:

Role of RRT in HRS:

RRT does NOT treat HRS - it is purely supportive therapy for complications:

• Hyperkalaemia refractory to medical therapy
• Metabolic acidosis refractory to medical therapy
• Volume overload refractory to diuretics
• Uraemic complications

In This Case - Key Question: Is the patient still a transplant candidate?

If Transplant Still Expected:

• Continue RRT as BRIDGE TO TRANSPLANT
• Inform transplant team of RRT status
• Combined liver-kidney transplant may be indicated if:
  • RRT >8-12 weeks (varies by centre)
  • Pre-transplant eGFR <25-30 mL/min for >6-12 weeks
  • Evidence of structural kidney disease
• Duration of RRT pre-transplant affects post-transplant outcomes

If Transplant Unlikely or Prolonged Wait:

• Goals of care discussion becomes critical
• Without transplant, RRT in HRS is futile:
  • Does not improve underlying condition
  • Prolongs dying process without benefit
  • "Median survival on RRT without transplant: <3 months"
• Consider withdrawal of RRT if patient/family agree

Decision Framework:

1. What is the realistic chance of transplant occurring?
   • Organ availability (MELD 38 gives high priority)
   • Patient's trajectory (is she deteriorating?)
2. What would the patient want?
   • Substitute judgment by family if patient cannot participate
   • Quality vs quantity of life
3. What is the burden of treatment?
   • Dialysis may be uncomfortable
   • ICU stay away from family and Country

In This Case:

• Patient is on waitlist with high MELD - transplant could still occur
• Would continue RRT as bridge to transplant
• However, if clinical deterioration continues (multi-organ failure, sepsis), would have goals of care discussion about treatment limitation
• Involve palliative care for symptom management regardless of decision

---

Follow-up Question 3 (2-3 minutes):

"What specific considerations are there for Aboriginal and Torres Strait Islander patients with liver disease?"

Expected Answer:

Epidemiology:

• 2-3x higher rates of chronic liver disease
• Higher hepatitis B prevalence (especially Northern Territory)
• Higher alcohol-related liver disease
• Often younger age at presentation with decompensated cirrhosis
• Diabetes and metabolic risk factors more prevalent

Barriers to Transplant Access:

1. Geographic:

   • Remote location - distance from transplant centres (Perth, Adelaide, Brisbane nearest for NT)
   • Need to relocate for extended periods pre- and post-transplant
   • Connection to Country makes relocation distressing

2. Socioeconomic:

   • Accommodation during treatment
   • Financial stress
   • Employment, family care responsibilities

3. Cultural:

   • Different health beliefs and priorities
   • Importance of family and community involvement in decisions
   • May have distrust of healthcare system (historical context)
   • Language barriers

4. Systemic:

   • Lower rates of referral to transplant services
   • May not be offered transplant assessment at same rate
   • Higher waitlist attrition (become too sick or die waiting)
   • Implicit bias in healthcare decision-making

Best Practices:

• Early referral for transplant assessment (lower threshold)
• Involve Aboriginal Health Workers throughout care
• Cultural safety training for all staff
• Telehealth for pre-transplant work-up where possible
• Support for relocation (accommodation, family support)
• Flexible visiting arrangements for family
• Consider repatriation if goals become palliative
• Recognise and address systemic barriers
• Advocate for equity in transplant access

This Patient:

• From remote NT community - significant geographic barriers
• May want to return to Country if prognosis poor
• Family involvement in decision-making crucial
• Ensure Aboriginal Liaison Officer involved
• Discuss with transplant team options for continued waitlisting vs palliation

---

Examiner's Expected Level:

Pass:

• Correctly identifies poor prognostic factors
• Demonstrates compassionate, culturally safe communication approach
• Understands RRT role as bridge to transplant only
• Aware of Indigenous health disparities and barriers to care
• Discusses goals of care appropriately

Fail:

• Cannot assess prognosis
• Poor communication skills or culturally inappropriate approach
• Does not recognise futility of RRT without transplant
• Unaware of Indigenous health considerations
• Avoids or mishandles goals of care discussion